PMID- 15597148
OWN - NLM
STAT- MEDLINE
DCOM- 20050324
LR  - 20181201
IS  - 1023-3830 (Print)
IS  - 1023-3830 (Linking)
VI  - 53
IP  - 10
DP  - 2004 Oct
TI  - Hyaluronan enhances cartilage repair through low grade tissue remodeling 
      involving cytokines and matrix metalloproteinases.
PG  - 534-43
AB  - OBJECTIVE AND DESIGN: To determine whether the ability of high molecular weight 
      hyaluronan (HA) to reverse cartilage damage caused by specific catabolic 
      mediators of cartilage damage, fibronectin fragments (Fn-fs), occurs through a 
      low grade of enhanced catabolic events such as enhanced matrix metalloproteinase 
      (MMP) expression or cytokine activities. MATERIAL: HA from 6.8-kDa to 2 million 
      daltons was studied. TREATMENT: The ability of HA to enhance matrix 
      metalloproteinase-3 (MMP-3) epitopes and cartilage proteoglycan (PG) degradation 
      neoepitopes was tested in bovine cartilage, as well as the ability of recombinant 
      human interleukin-1 receptor antagonist protein (rhIRAP) to reverse PG depletion 
      in cartilage first exposed to Fn-f. RESULTS: All HA forms enhanced MMP-3 epitopes 
      and PG degradation in normal undamaged cartilage and in the case of HA800, the 
      degradation was not sufficient to decrease steady state levels of cartilage PG. 
      When HA800 was added to Fn-f damaged cartilage, restoration of PG occurred, but 
      this was blocked by rhIRAP. CONCLUSIONS: These results collectively suggest that 
      some of the repair activity of HA800 is through proteolytic activity which is not 
      sufficient to decrease matrix PG content, but is nonetheless elevated above 
      levels in cartilage not treated with HA800.
FAU - Homandberg, G A
AU  - Homandberg GA
AD  - Department of Biochemistry and Molecular Biology, University of North Dakota 
      School of Medicine and Health Sciences, Box 9037, Grand Forks, ND 58202, USA. 
      ghomandb@medicine.nodak.edu
FAU - Ummadi, V
AU  - Ummadi V
FAU - Kang, H
AU  - Kang H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Culture Media, Serum-Free)
RN  - 0 (Cytokines)
RN  - 0 (Epitopes)
RN  - 0 (Fibronectins)
RN  - 0 (IL1RN protein, human)
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
RN  - 0 (Oligopeptides)
RN  - 0 (Peptide Fragments)
RN  - 0 (Prostaglandins)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Sialoglycoproteins)
RN  - 0 (peptide VDIPEN)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - EC 3.4.- (Endopeptidases)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - EC 3.4.99.- (aggrecanase)
RN  - J2VZ07J96K (Polymyxin B)
SB  - IM
MH  - Animals
MH  - Blotting, Western
MH  - Cartilage/*drug effects/metabolism
MH  - Cattle
MH  - Culture Media, Conditioned/pharmacology
MH  - Culture Media, Serum-Free/metabolism
MH  - Cytokines/*metabolism
MH  - Endopeptidases/chemistry
MH  - Epitopes/chemistry
MH  - Fibronectins/chemistry/metabolism
MH  - Humans
MH  - Hyaluronic Acid/*chemistry/*pharmacology
MH  - Immunohistochemistry
MH  - Insulin-Like Growth Factor I/metabolism
MH  - Interleukin 1 Receptor Antagonist Protein
MH  - Kinetics
MH  - Matrix Metalloproteinase 3/chemistry
MH  - Matrix Metalloproteinases/*metabolism
MH  - Oligopeptides/chemistry
MH  - Peptide Fragments/chemistry
MH  - Polymyxin B/chemistry
MH  - Prostaglandins/metabolism
MH  - Recombinant Proteins/chemistry
MH  - Sialoglycoproteins/chemistry
MH  - Time Factors
EDAT- 2004/12/15 09:00
MHDA- 2005/03/25 09:00
CRDT- 2004/12/15 09:00
PHST- 2004/12/15 09:00 [pubmed]
PHST- 2005/03/25 09:00 [medline]
PHST- 2004/12/15 09:00 [entrez]
AID - 10.1007/s00011-004-1292-y [doi]
PST - ppublish
SO  - Inflamm Res. 2004 Oct;53(10):534-43. doi: 10.1007/s00011-004-1292-y.